Impel NeuroPharma: Publication of Pivotal Phase 3 Study of Migraine Treatment

 Study Shows TRUDHESA™ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief

Exploratory Patient-Reported Outcomes Data Indicated More Than One Third of Patients Experienced Pain Freedom and Two Thirds Had Pain Relief Two Hours Following TRUDHESA™ Administration

Among the 38 Percent of Patients Who Self-Reported Two-Hour Pain Freedom for Their First TRUDHESA™- Treated Attack, only 7.1 Percent and 14.3 Percent of Patients Reported Recurrence of Migraine at 24 and 48 hours post TRUDHESA™ Administration, Respectively

The U.S. FDA Has Accepted TRUDHESA™ for Review with a Target PDUFA Date of September 6, 2021

https://finance.yahoo.com/news/impel-neuropharma-announces-publication-pivotal-120000075.html